DK1856090T3 - Substituerede thiophen-derivater som glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser - Google Patents

Substituerede thiophen-derivater som glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser

Info

Publication number
DK1856090T3
DK1856090T3 DK06720513T DK06720513T DK1856090T3 DK 1856090 T3 DK1856090 T3 DK 1856090T3 DK 06720513 T DK06720513 T DK 06720513T DK 06720513 T DK06720513 T DK 06720513T DK 1856090 T3 DK1856090 T3 DK 1856090T3
Authority
DK
Denmark
Prior art keywords
glucagon receptor
preparation
receptor antagonists
compounds
therapeutic applications
Prior art date
Application number
DK06720513T
Other languages
Danish (da)
English (en)
Inventor
Mark Donald Chappell
Scott Eugene Conner
Allie Edward Tripp
Guoxin Zhu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36694345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1856090(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1856090T3 publication Critical patent/DK1856090T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK06720513T 2005-02-11 2006-02-09 Substituerede thiophen-derivater som glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser DK1856090T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65249205P 2005-02-11 2005-02-11
PCT/US2006/004461 WO2006086488A2 (en) 2005-02-11 2006-02-09 Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses

Publications (1)

Publication Number Publication Date
DK1856090T3 true DK1856090T3 (da) 2009-11-30

Family

ID=36694345

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06720513T DK1856090T3 (da) 2005-02-11 2006-02-09 Substituerede thiophen-derivater som glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser

Country Status (25)

Country Link
US (1) US8084489B2 (cg-RX-API-DMAC7.html)
EP (1) EP1856090B1 (cg-RX-API-DMAC7.html)
JP (1) JP4988604B2 (cg-RX-API-DMAC7.html)
KR (1) KR20070104409A (cg-RX-API-DMAC7.html)
CN (1) CN101115735B (cg-RX-API-DMAC7.html)
AT (1) ATE445609T1 (cg-RX-API-DMAC7.html)
AU (1) AU2006213894B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0607015A2 (cg-RX-API-DMAC7.html)
CA (1) CA2597073C (cg-RX-API-DMAC7.html)
CR (1) CR9304A (cg-RX-API-DMAC7.html)
CY (1) CY1109624T1 (cg-RX-API-DMAC7.html)
DE (1) DE602006009773D1 (cg-RX-API-DMAC7.html)
DK (1) DK1856090T3 (cg-RX-API-DMAC7.html)
EA (1) EA200701705A1 (cg-RX-API-DMAC7.html)
ES (1) ES2332470T3 (cg-RX-API-DMAC7.html)
IL (1) IL184932A0 (cg-RX-API-DMAC7.html)
MA (1) MA29432B1 (cg-RX-API-DMAC7.html)
MX (1) MX2007009661A (cg-RX-API-DMAC7.html)
NO (1) NO20074567L (cg-RX-API-DMAC7.html)
PL (1) PL1856090T3 (cg-RX-API-DMAC7.html)
PT (1) PT1856090E (cg-RX-API-DMAC7.html)
SI (1) SI1856090T1 (cg-RX-API-DMAC7.html)
TN (1) TNSN07313A1 (cg-RX-API-DMAC7.html)
WO (1) WO2006086488A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200706354B (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1758853E (pt) * 2004-06-14 2010-03-02 Lilly Co Eli Antagonistas do receptor de glucagon, sua preparação e usos terapêuticos
KR101538810B1 (ko) 2007-02-09 2015-07-22 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
BRPI0918004B8 (pt) 2008-08-13 2021-05-25 Metabasis Therapeutics Inc compostos antagonistas e agonistas inversos de receptores de glucagon, composição farmacêutica e uso dos compostos
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
KR101506829B1 (ko) 2010-12-23 2015-03-30 화이자 인코포레이티드 글루카곤 수용체 조절제
KR101585840B1 (ko) 2011-02-08 2016-01-15 화이자 인코포레이티드 글루카곤 수용체 조절자
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
BR112014000288A2 (pt) 2011-07-22 2017-01-10 Pfizer moduladores do receptor de glucagon de quinolinila
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
TW201427658A (zh) 2012-12-10 2014-07-16 Merck Sharp & Dohme 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
US9649294B2 (en) 2013-11-04 2017-05-16 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2015191900A1 (en) 2014-06-12 2015-12-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
US10829519B2 (en) 2015-09-18 2020-11-10 Wake Forest University Health Sciences Angiotensin (1-7) analogs and methods relating thereto
EP3821917A1 (en) 2015-10-05 2021-05-19 Hettwer Holding ApS Compositions and methods for treatment of bone defects
CA2914601A1 (en) * 2015-12-11 2017-06-11 Wake Forest University Health Sciences Angiotensin-(1-7) analogs and methods relating thereto
KR20190044079A (ko) 2016-08-30 2019-04-29 리제너론 파마슈티칼스 인코포레이티드 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법
US20190248888A1 (en) 2016-10-20 2019-08-15 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
EP3672620A1 (en) 2017-08-22 2020-07-01 Regeneron Pharmaceuticals, Inc. Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
US12208071B2 (en) 2018-02-13 2025-01-28 Ligand Pharmaceuticals Incorporated Glucagon receptor antagonists
BR112022010735A2 (pt) 2019-12-20 2022-08-23 Bayer Ag Tiofeno carboxamidas substituídos, ácidos tiofeno carboxílicos e derivados dos mesmos

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005511683A (ja) 2001-12-03 2005-04-28 ノボ ノルディスク アクティーゼルスカブ 新規なグルカゴンアンタゴニスト
JP2006500325A (ja) * 2002-06-27 2006-01-05 ノボ ノルディスク アクティーゼルスカブ 新規なグルカゴンアンタゴニスト
WO2005118542A1 (en) 2004-05-28 2005-12-15 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
PT1758853E (pt) * 2004-06-14 2010-03-02 Lilly Co Eli Antagonistas do receptor de glucagon, sua preparação e usos terapêuticos

Also Published As

Publication number Publication date
PT1856090E (pt) 2009-11-18
BRPI0607015A2 (pt) 2009-12-01
EA200701705A1 (ru) 2008-02-28
TNSN07313A1 (en) 2008-12-31
CY1109624T1 (el) 2014-08-13
EP1856090A2 (en) 2007-11-21
WO2006086488A3 (en) 2006-12-14
JP2008530102A (ja) 2008-08-07
AU2006213894A1 (en) 2006-08-17
WO2006086488A2 (en) 2006-08-17
JP4988604B2 (ja) 2012-08-01
MA29432B1 (fr) 2008-05-02
ZA200706354B (en) 2008-11-26
ES2332470T3 (es) 2010-02-05
MX2007009661A (es) 2007-09-25
CA2597073C (en) 2014-11-25
CA2597073A1 (en) 2006-08-17
US8084489B2 (en) 2011-12-27
US20100137417A1 (en) 2010-06-03
AU2006213894B2 (en) 2011-12-08
NO20074567L (no) 2007-11-08
CN101115735B (zh) 2013-01-09
CN101115735A (zh) 2008-01-30
DE602006009773D1 (de) 2009-11-26
SI1856090T1 (sl) 2010-02-26
PL1856090T3 (pl) 2010-02-26
KR20070104409A (ko) 2007-10-25
EP1856090B1 (en) 2009-10-14
ATE445609T1 (de) 2009-10-15
CR9304A (es) 2008-03-31
IL184932A0 (en) 2007-12-03

Similar Documents

Publication Publication Date Title
DK1856090T3 (da) Substituerede thiophen-derivater som glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
NO20070213L (no) Glucagon reseptorantagonister, fremstilling og terapeutiske anvendelser
CY1110922T1 (el) Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις
WO2007106181A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
DK1735278T3 (da) Histamin H3-receptormidler, fremstilling og terapeutiske anvendelser
WO2007120270A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
CY1109694T1 (el) Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης
DK1951659T3 (da) Glucagonreceptorantagonister, fremstilling og terapeutisk anvendelse heraf